学习园地

FDA批准Magstim Horizon INSPIRE经颅磁刺激系统用于治疗抑郁症、强迫症及焦虑型抑郁症* 新一代紧凑型TMS系统为医师及护理师提供高效经济的创新治疗方案

发布时间：2025-06-03 10:11:41   来源：本站   点击：15次

　　美国明尼苏达州明尼阿波利斯市 & 英国卡马森郡——(2024年11月12日)——全球神经科学与精神健康治疗领域的领导者Magstim宣布，其Horizon INSPIRE系统正式获得美国FDA批准。该突破性经颅磁刺激(TMS)技术将为医师、护理师、临床医生及研究人员提供新一代治疗方案，适用于重性抑郁症(MDD)、强迫症(OCD)及焦虑型抑郁症*的治疗。

　　满足临床迫切需求

　　"医疗专业人员反馈，患者亟需药物治疗之外的替代方案，"Magstim首席执行官Ronnie Stolec-Campo表示，"FDA批准的经颅磁刺激疗法已被证实具有卓越疗效且副作用极小。INSPIRE系统既适合TMS经验丰富的医师，也方便新手快速掌握。"

　　技术创新亮点

　　• 高效风冷系统：支持连续定制化治疗，无需等待冷却

　　• 智能临床流程：预设标准化治疗方案，确保精准剂量输出

　　• 经济便携设计：诊室间灵活调配，显著降低运营成本

　　• 数据驱动优化：先进分析工具实时提升治疗效果

　　行业权威背书

　　INSPIRE系统基于Magstim核心TMS技术打造，该技术已获：

　　✓ 20,000+篇同行评审研究论文引用

　　✓ 全球医院、诊所及研究中心的广泛应用

　　✓ 多数保险公司(含Medicare)的诊疗覆盖

　　市场趋势

　　最新研究(**)显示，经颅磁刺激在MDD和OCD治疗中展现显著优势，推动其全球应用快速增长。目前美国多数州已允许精神科护理师(PMHNP)开展TMS治疗。

　　"作为商用TMS技术的开创者，我们始终坚持科研为本，"Stolec-Campo强调，"Magstim的独特性在于：不收取单次使用费、拥有专属服务支持团队，并坚持自主生产技术。"

　　FDA Clears Magstim Horizon INSPIRE Transcranial Magnetic Stimulation System to treat Depression, OCD, Anxious Depression FDA Clears Magstim Horizon INSPIRE Transcranial Magnetic Stimulation System to treat Depression, OCD, Anxious Depression* Next Generation Compact TMS System Offers Physicians, Nurse Practitioners, New Easy to Use, Affordable Effective Treatment MINNEAPOLIS, Minn. & Carmarthenshire, UK -- (November 12, 2024) – Magstim, the global leader in neuroscience research and treatment for mental health, has been awarded FDA clearance for the Horizon Inspire System, continuing to provide physicians, nurse practitioners, clinicians, and researchers with next-generation transcranial magnetic stimulation technology to treat patients with MDD, OCD and Anxious Depression*. “Physicians, nurse practitioners and mental health care professionals tell us that patients are searching for alternatives to pharmaceutical treatments,” said Ronnie Stolec-Campo, CEO, Magstim. “FDA cleared transcranial magnetic stimulation is a proven and effective treatment with minimal side effects. We designed the Inspire to enable both experienced TMS providers as well as those who are new to TMS.” According to Stolec-Campo, professionals requested a system to quickly launch their TMS practice. The Inspire addresses their needs with high-power air-cooling, ability to deliver back-to-back customizable treatments, all while being easy to use, cost-effective and offering portability between clinic rooms. The Inspire is built on Magstim TMS technology, cited in more than 20,000 peer reviewed research papers and used in hospitals, clinics and research centers worldwide. The Inspire offers a powerful and versatile system to comfortably treat patients with mental health disorders. The use of Transcranial Magnetic Stimulation for treating MDD and OCD is increasing worldwide, driven by new studies demonstrating its effectiveness over other treatments (**). TMS is now covered by most insurance companies, including Medicare. Many states now permit both physicians and psychiatric nurse practitioners (PMHNP) to prescribe and treat patients with TMS. The Inspire system leverages intuitive preset clinical workflows to simplify the treatment process, delivering precise results with no pulse decay, ensuring the correct dosage. Magstim’s air-cooled coil reduces downtime and eliminates additional cooling expenses. Advanced data analytics tools improve treatment efficacy. “Magstim engineered the very first commercially available TMS research technology, and we remain committed to our foundation of research” said Stolec-Campo. “We are unique in the industry because we do not charge pay per use fees, we maintain a dedicated service and support team, and we manufacture our own technology.”